USE OF GENE THERAPY TO INDUCE TRANSPLANT TOLERANCE

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。目的：对终末期疾病患者进行异种移植是解决人体器官供体短缺的一种潜在方法。人类排斥来自猪供体的移植物，是因为预先存在针对由α 1,3-半乳糖转移酶合成的α 1,3-半乳糖碳水化合物的天然异种抗体。这种酶在人类、猿类或旧大陆猴子中没有表达。因此，这些物种产生针对在猪细胞上表达的半乳糖碳水化合物的异种抗体。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Objective: Xenograft transplantation for patients with end-stage diseases represents a potential solution to the shortage of human organ donors. Humans reject grafts from porcine donors due to pre-existing natural xenoantibodies directed at the gal alpha1,3gal carbohydrate which is synthesized by alpha1,3-galactosyltransferase. This enzyme is not expressed in humans, apes, or old world monkeys. These species, therefore, produce xenoantibodies directed at the gal carbohydrate which is expressed on pig cells.